GLSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (11 4月 2023 @ 05:00):

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases...

Stats
本日の出来高	185 167
平均出来高	570 667
時価総額	11.63M
EPS	$0 ( 2024-03-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.122
ATR14	$0.0180 (148.76%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-20	Puretech Health Plc	Buy	0	Convertible Note
2023-06-12	Puretech Health Plc	Buy	0	Convertible Note
2023-05-26	Puretech Health Plc	Buy	43 133 803	Warrants
2023-05-26	Puretech Health Plc	Buy	0	Convertible Note
2023-05-01	Puretech Health Plc	Buy	192 307 692	Warrants

INSIDER POWER
99.97
Last 86 transactions
Buy: 269 373 579 \| Sell: 26 728 050

ボリューム相関

長: -0.10 (neutral)

短: -0.99 (very strong negative)

Signal:(31.483) Neutral

Gelesis Holdings, Inc. 相関

10 最も正の相関
TBI	0.855
VFC	0.849
NBHC	0.848
AFG	0.839
AUD	0.836
HP	0.832
COP	0.827
ETRN	0.825
DVN	0.822
BOC	0.821

10 最も負の相関
DSE	-0.846
IOT	-0.83
BBL	-0.812
IDT	-0.811
MIC	-0.811
FPAC-UN	-0.805
YEXT	-0.805

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Gelesis Holdings, Inc. 相関 - 通貨/商品

-0.85
( strong negative )

-0.84
( strong negative )

0.00
( neutral )

-0.93
( very strong negative )

0.66
( moderate )

Gelesis Holdings, Inc. 財務諸表

Annual	2022
収益:	$25.77M
総利益:	$-1.79M (-6.95 %)
EPS:	$-0.790

FY	2022
収益:	$25.77M
総利益:	$-1.79M (-6.95 %)
EPS:	$-0.790

FY	2021
収益:	$11.19M
総利益:	$1.20M (10.75 %)
EPS:	$-0.0423

Financial Reports:

No articles found.

Gelesis Holdings, Inc.

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.